礼来公司表示,在2型糖尿病试验中,其口服GLP-1药物Orforglipron在血糖控制和减重方面均优于诺和诺德的口服司美格鲁肽。
礼来公司表示,在2型糖尿病试验中,其口服GLP-1药物Orforglipron在血糖控制和减重方面均优于诺和诺德的口服司美格鲁肽。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.